Browse by author
Lookup NU author(s): Professor Andrew FisherORCiD
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
© 2024 The AuthorsPrevention and management of allograft rejection urgently require more effective therapeutic solutions. Current immunosuppressive therapies used in solid organ transplantation, while effective in reducing the risk of acute rejection, are associated with substantial adverse effects. There is, therefore, a need for agents that can provide immunomodulation, supporting graft tolerance, while minimizing the need for immunosuppression. Extracorporeal photopheresis (ECP) is an immunomodulatory therapy currently recommended in international guidelines as an adjunctive treatment for the prevention and management of organ rejection in heart and lung transplantations. This article reviews clinical experience and ongoing research with ECP for organ rejection in heart and lung transplantations, as well as emerging findings in kidney and liver transplantation. ECP, due to its immunomodulatory and immunosuppressive-sparing effects, offers a potential therapeutic option in these settings, particularly in high-risk patients with comorbidities, infectious complications, or malignancies.
Author(s): Barten MJ, Fisher AJ, Hertig A
Publication type: Review
Publication status: Published
Journal: American Journal of Transplantation
Year: 2024
Pages: epub ahead of print
Online publication date: 14/03/2024
Acceptance date: 10/03/2024
ISSN (print): 1600-6135
ISSN (electronic): 1600-6143
Publisher: Elsevier B.V.
URL: https://doi.org/10.1016/j.ajt.2024.03.012
DOI: 10.1016/j.ajt.2024.03.012
PubMed id: 38490642
